AVTX
Avalo Therapeutics IncKey Statistics
About Avalo Therapeutics Inc
Avalo Therapeutics Inc is a prominent clinical-stage biotechnology company focused on developing innovative therapies for rare and underserved diseases, particularly those involving immunological regulation. The firm has a robust pipeline of proprietary drug candidates aimed at addressing serious conditions with significant unmet medical needs, reflecting its commitment to advancing healthcare solutions. Avalo's deep expertise in disease mechanisms and comprehensive clinical trial methodologies position it strategically within the biopharmaceutical landscape, enabling the development of transformative therapies. With a strong patient-centric approach, Avalo is poised to enhance therapeutic outcomes and drive meaningful impacts in the lives of patients.
Fundamentals
| Revenue (TTM) | 59,000 |
| Gross Profit (TTM) | $-35.29M |
| EBITDA | $-72.58M |
| Operating Margin | -33461.00% |
| Return on Equity | -72.40% |
| Return on Assets | -34.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.49 |
| Price-to-Book | 3.53 |
| Price-to-Sales (TTM) | 4967.11 |
| EV/Revenue | 3307.04 |
| EV/EBITDA | -0.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -69.30% |
| Shares Outstanding | $22.79M |
| Float | $20.14M |
| % Insiders | 2.58% |
| % Institutions | 90.14% |
Historical Volatility
Volatility is currently expanding